Global Benign Prostatic Hyperplasia Therapeutics Market Size, Status and Forecast 2020-2026

May 2020 | 91 pages | ID: G6728E14D549EN
QYResearch

Abstracts

This report focuses on the global Benign Prostatic Hyperplasia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Benign Prostatic Hyperplasia Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

• Abbott Laboratories
• Allergan plc
• Astellas Pharma
• Boehringer Ingelheim Pharma GmbH and Co. KG
• Eli Lilly and Company
• GlaxoSmithKline plc
• Merck and Co.
• Pfizer
• Sanofi
• Teva Pharmaceutical Industries Limited

Market segment by Type, the product can be split into

• Alpha Blocker
• 5-Alpha Reductase Inhibitor
• Phosphodiesterase-5 Inhibitor
• Others

Market segment by Application, split into

• Mono Drug Therapy
• Combination Drug Therapy

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Benign Prostatic Hyperplasia Therapeutics status, future forecast, growth opportunity, key market and key players.
• To present the Benign Prostatic Hyperplasia Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Benign Prostatic Hyperplasia Therapeutics are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Benign Prostatic Hyperplasia Therapeutics Revenue
1.4 Market Analysis by Type
  1.4.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Alpha Blocker
  1.4.3 5-Alpha Reductase Inhibitor
  1.4.4 Phosphodiesterase-5 Inhibitor
  1.4.5 Others
1.5 Market by Application
  1.5.1 Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application: 2020 VS 2026
  1.5.2 Mono Drug Therapy
  1.5.3 Combination Drug Therapy
1.6 Study Objectives
1.7 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Benign Prostatic Hyperplasia Therapeutics Market Perspective (2015-2026)
2.2 Benign Prostatic Hyperplasia Therapeutics Growth Trends by Regions
  2.2.1 Benign Prostatic Hyperplasia Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Benign Prostatic Hyperplasia Therapeutics Historic Market Share by Regions (2015-2020)
  2.2.3 Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Benign Prostatic Hyperplasia Therapeutics Market Growth Strategy
  2.3.6 Primary Interviews with Key Benign Prostatic Hyperplasia Therapeutics Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Market Size
  3.1.1 Global Top Benign Prostatic Hyperplasia Therapeutics Players by Revenue (2015-2020)
  3.1.2 Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Players (2015-2020)
  3.1.3 Global Benign Prostatic Hyperplasia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio
  3.2.1 Global Benign Prostatic Hyperplasia Therapeutics Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia Therapeutics Revenue in 2019
3.3 Benign Prostatic Hyperplasia Therapeutics Key Players Head office and Area Served
3.4 Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
3.5 Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Benign Prostatic Hyperplasia Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Type (2021-2026)

5 BENIGN PROSTATIC HYPERPLASIA THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)
5.2 Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
6.2 Benign Prostatic Hyperplasia Therapeutics Key Players in North America (2019-2020)
6.3 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
6.4 North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
7.2 Benign Prostatic Hyperplasia Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
7.4 Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

8 CHINA

8.1 China Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
8.2 Benign Prostatic Hyperplasia Therapeutics Key Players in China (2019-2020)
8.3 China Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
8.4 China Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
9.2 Benign Prostatic Hyperplasia Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
9.4 Japan Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
10.2 Benign Prostatic Hyperplasia Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

11 INDIA

11.1 India Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
11.2 Benign Prostatic Hyperplasia Therapeutics Key Players in India (2019-2020)
11.3 India Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
11.4 India Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Benign Prostatic Hyperplasia Therapeutics Market Size (2015-2020)
12.2 Benign Prostatic Hyperplasia Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Abbott Laboratories
  13.1.1 Abbott Laboratories Company Details
  13.1.2 Abbott Laboratories Business Overview and Its Total Revenue
  13.1.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Introduction
  13.1.4 Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020))
  13.1.5 Abbott Laboratories Recent Development
13.2 Allergan plc
  13.2.1 Allergan plc Company Details
  13.2.2 Allergan plc Business Overview and Its Total Revenue
  13.2.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Introduction
  13.2.4 Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.2.5 Allergan plc Recent Development
13.3 Astellas Pharma
  13.3.1 Astellas Pharma Company Details
  13.3.2 Astellas Pharma Business Overview and Its Total Revenue
  13.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Introduction
  13.3.4 Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.3.5 Astellas Pharma Recent Development
13.4 Boehringer Ingelheim Pharma GmbH and Co. KG
  13.4.1 Boehringer Ingelheim Pharma GmbH and Co. KG Company Details
  13.4.2 Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview and Its Total Revenue
  13.4.3 Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Introduction
  13.4.4 Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.4.5 Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
13.5 Eli Lilly and Company
  13.5.1 Eli Lilly and Company Company Details
  13.5.2 Eli Lilly and Company Business Overview and Its Total Revenue
  13.5.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Introduction
  13.5.4 Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.5.5 Eli Lilly and Company Recent Development
13.6 GlaxoSmithKline plc
  13.6.1 GlaxoSmithKline plc Company Details
  13.6.2 GlaxoSmithKline plc Business Overview and Its Total Revenue
  13.6.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Introduction
  13.6.4 GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.6.5 GlaxoSmithKline plc Recent Development
13.7 Merck and Co.
  13.7.1 Merck and Co. Company Details
  13.7.2 Merck and Co. Business Overview and Its Total Revenue
  13.7.3 Merck and Co. Benign Prostatic Hyperplasia Therapeutics Introduction
  13.7.4 Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.7.5 Merck and Co. Recent Development
13.8 Pfizer
  13.8.1 Pfizer Company Details
  13.8.2 Pfizer Business Overview and Its Total Revenue
  13.8.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Introduction
  13.8.4 Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.8.5 Pfizer Recent Development
13.9 Sanofi
  13.9.1 Sanofi Company Details
  13.9.2 Sanofi Business Overview and Its Total Revenue
  13.9.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Introduction
  13.9.4 Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.9.5 Sanofi Recent Development
13.10 Teva Pharmaceutical Industries Limited
  13.10.1 Teva Pharmaceutical Industries Limited Company Details
  13.10.2 Teva Pharmaceutical Industries Limited Business Overview and Its Total Revenue
  13.10.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Introduction
  13.10.4 Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
  13.10.5 Teva Pharmaceutical Industries Limited Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Benign Prostatic Hyperplasia Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Benign Prostatic Hyperplasia Therapeutics Revenue
Table 3. Ranking of Global Top Benign Prostatic Hyperplasia Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Alpha Blocker
Table 6. Key Players of 5-Alpha Reductase Inhibitor
Table 7. Key Players of Phosphodiesterase-5 Inhibitor
Table 8. Key Players of Others
Table 9. Global Benign Prostatic Hyperplasia Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 10. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 11. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 12. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Regions (2015-2020)
Table 13. Global Benign Prostatic Hyperplasia Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 14. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Regions (2021-2026)
Table 15. Market Top Trends
Table 16. Key Drivers: Impact Analysis
Table 17. Key Challenges
Table 18. Benign Prostatic Hyperplasia Therapeutics Market Growth Strategy
Table 19. Main Points Interviewed from Key Benign Prostatic Hyperplasia Therapeutics Players
Table 20. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 21. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players (2015-2020)
Table 22. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2019)
Table 23. Global Benign Prostatic Hyperplasia Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 24. Key Players Headquarters and Area Served
Table 25. Key Players Benign Prostatic Hyperplasia Therapeutics Product Solution and Service
Table 26. Date of Enter into Benign Prostatic Hyperplasia Therapeutics Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 29. Global Benign Prostatic Hyperplasia Therapeutics Market Size Share by Type (2015-2020)
Table 30. Global Benign Prostatic Hyperplasia Therapeutics Revenue Market Share by Type (2021-2026)
Table 31. Global Benign Prostatic Hyperplasia Therapeutics Market Size Share by Application (2015-2020)
Table 32. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 33. Global Benign Prostatic Hyperplasia Therapeutics Market Size Share by Application (2021-2026)
Table 34. North America Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 35. North America Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 36. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 37. North America Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 38. North America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 39. North America Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 40. Europe Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 41. Europe Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 42. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 43. Europe Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 44. Europe Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 45. Europe Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 46. China Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 47. China Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 48. China Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 49. China Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 50. China Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 51. China Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 52. Japan Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 53. Japan Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 54. Japan Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 55. Japan Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 56. Japan Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 57. Japan Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 58. Southeast Asia Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 59. Southeast Asia Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 60. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 61. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 62. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 63. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 64. India Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 65. India Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 66. India Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 67. India Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 68. India Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 69. India Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 70. Central & South America Key Players Benign Prostatic Hyperplasia Therapeutics Revenue (2019-2020) (Million US$)
Table 71. Central & South America Key Players Benign Prostatic Hyperplasia Therapeutics Market Share (2019-2020)
Table 72. Central & South America Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 73. Central & South America Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2015-2020)
Table 74. Central & South America Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 75. Central & South America Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2015-2020)
Table 76. Abbott Laboratories Company Details
Table 77. Abbott Laboratories Business Overview
Table 78. Abbott Laboratories Product
Table 79. Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 80. Abbott Laboratories Recent Development
Table 81. Allergan plc Company Details
Table 82. Allergan plc Business Overview
Table 83. Allergan plc Product
Table 84. Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 85. Allergan plc Recent Development
Table 86. Astellas Pharma Company Details
Table 87. Astellas Pharma Business Overview
Table 88. Astellas Pharma Product
Table 89. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 90. Astellas Pharma Recent Development
Table 91. Boehringer Ingelheim Pharma GmbH and Co. KG Company Details
Table 92. Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
Table 93. Boehringer Ingelheim Pharma GmbH and Co. KG Product
Table 94. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 95. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
Table 96. Eli Lilly and Company Company Details
Table 97. Eli Lilly and Company Business Overview
Table 98. Eli Lilly and Company Product
Table 99. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 100. Eli Lilly and Company Recent Development
Table 101. GlaxoSmithKline plc Company Details
Table 102. GlaxoSmithKline plc Business Overview
Table 103. GlaxoSmithKline plc Product
Table 104. GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 105. GlaxoSmithKline plc Recent Development
Table 106. Merck and Co. Company Details
Table 107. Merck and Co. Business Overview
Table 108. Merck and Co. Product
Table 109. Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 110. Merck and Co. Recent Development
Table 111. Pfizer Business Overview
Table 112. Pfizer Product
Table 113. Pfizer Company Details
Table 114. Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 115. Pfizer Recent Development
Table 116. Sanofi Company Details
Table 117. Sanofi Business Overview
Table 118. Sanofi Product
Table 119. Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 120. Sanofi Recent Development
Table 121. Teva Pharmaceutical Industries Limited Company Details
Table 122. Teva Pharmaceutical Industries Limited Business Overview
Table 123. Teva Pharmaceutical Industries Limited Product
Table 124. Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020) (Million US$)
Table 125. Teva Pharmaceutical Industries Limited Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Alpha Blocker Features
Figure 3. 5-Alpha Reductase Inhibitor Features
Figure 4. Phosphodiesterase-5 Inhibitor Features
Figure 5. Others Features
Figure 6. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application: 2020 VS 2026
Figure 7. Mono Drug Therapy Case Studies
Figure 8. Combination Drug Therapy Case Studies
Figure 9. Benign Prostatic Hyperplasia Therapeutics Report Years Considered
Figure 10. Global Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Players in 2019
Figure 15. Global Top Benign Prostatic Hyperplasia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Benign Prostatic Hyperplasia Therapeutics Revenue in 2019
Figure 17. North America Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Benign Prostatic Hyperplasia Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Abbott Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Abbott Laboratories Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 26. Allergan plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 28. Astellas Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 30. Boehringer Ingelheim Pharma GmbH and Co. KG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 32. Eli Lilly and Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Eli Lilly and Company Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 34. GlaxoSmithKline plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. GlaxoSmithKline plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 36. Merck and Co. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Merck and Co. Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 38. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 40. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 42. Teva Pharmaceutical Industries Limited Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2015-2020)
Figure 44. Bottom-up and Top-down Approaches for This Report
Figure 45. Data Triangulation
Figure 46. Key Executives Interviewed